Kornimate/medical-research-clean huggingface dataset:
efficacy of small bowel preparation in capsule endoscopy

Conditions: Gastrointestinal Bleedings

Summary: the best preparation of small bowel is still unknown. the primary aim of this study is to evaluate the polyethylene glycol (peg) impact of small bowel preparation for unexplained gastrointestinal bleeding exploration. three different preparations are evaluated in this study.

now days, the endoscopic video-capsule is the more appropriate exam for unexplained gastrointestinal bleeding exploration. the responsible damage of this unexplained bleeding are frequently small vascular damages, hard to be detected in the bowel or ulcerations or tumors. the exam quality can be limited by food residues, bubbles or bile. 30% of damage are probably undetectable because of a lack of visibility. an efficient preparation will probably increased the quality of the video-capsule exploration. the bowel exploration by endoscopy video-capsule will be realized in the usual condition. the study included 4 steps: 1. inclusion 2. randomization 3. video-capsule exploration 4. reading of the video-capsule exam by endoscopist doctors who are in blind.

Eligibility criteria:
inclusion criteria: * age \>= 18 years old. * patients who have an indication for video-capsule endoscopy exploration for unexplained gastrointestinal bleeding associated with anaemia (man : haemoglobin \<13 g/dl and woman haemoglobin \<12g/dl) * less than one year endoscopic assessment by colonoscopy and gastroscopy * not participated to an another clinic study. * written consent. exclusion criteria: * age\<18 years old. * general physical health deterioration such as dehydration or cardiac insufficiency. * clinical or radiological suspicion of digestive stenosis. * oral iron taking in the 4 days before video-capsule exploration. * functional or organic disorders of the gulp * pregnant women. * sensibility known about the polyethylene glycol. * no signed consent.

Keywords: small bowel video-capsule endoscopy gastrointestinal bleeding polyethylene glycol
construction of a predictive model of gangrenous cholecystitis based on machine learning

Conditions: Gangrenous Cholecystitis

Summary: gangrenous cholecystitis is the most common complication of acute cholecystitis. there is no research using machine learning models to construct predictive diagnostic models for gangrenous cholecystitis.

this study reviewed the clinical data of 2023 cholecystectomy patients admitted to our center between january 1, 2015, and may 31, 2015, it includes demographic, clinical features, laboratory and imaging indexes, and constructs five commonly used decision tree, svm, random forest, xgboost, adaboost models, feature subsets are selected by recursive feature elimination with cross-validation and the importance of variables in each model, model performance is evaluated by balanced accuracy, recall, precision, f1score, and the precision-recall(pr) curve, and the final results are verified by independent external validation sets.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute cholecystitis or acute exacerbation of chronic cholecystitis in our hospital and receiving complete clinical treatment in our hospital; * performing cholecystectomy; * having complete and searchable clinical data, such as patient's age, surgical records, and hospitalization days. exclusion criteria: * previous diagnosis of chronic cholecystitis, this time for elective surgical treatment; * previous diagnosis of acute cholecystitis, ultrasound-guided cholecystectomy after elective laparoscopic cholecystectomy; * concomitant with other acute biliary and pancreatic system-related diseases, such as obstructive jaundice caused by choledochal stones, acute cholangitis, acute pancreatitis, etc.; * exclude patients who combined with other surgery patients such as choledochotomy and lithotripsy, choledochoscopic exploration and lithotripsy, bile-intestinal anastomosis, appendectomy, etc; * those with incomplete data
a clinical trial to evaluate dichloroacetate (dca) as a treatment for endometriosis-associated pain

Conditions: Endometriosis

Summary: this is a single-arm open label exploratory clinical trial to evaluate dichloroacetate (dca) as a possible treatment for treatment of endometriosis-associated pain

endometriosis is a chronic condition usually affecting women throughout their reproductive lives. it is defined as a growth of endometrial-like tissue (womb lining) outside the uterus (womb) and is associated with chronic pelvic pain that can be frequent and severe, resulting in tiredness, lower quality of life and difficulties in getting pregnant. current treatments are unsatisfactory and there is an unmet need for new medical treatment for endometriosis. research findings from our laboratory have shown that women with endometriosis have more lactate in their pelvis. in laboratory models of endometriosis, we have tested dichloroacetate (dca), a compound used to treat metabolic disorders in children. our results showed that dca could stop the growth and survival of endometriosis cells and reduce lactate production. in our study we plan to investigate if we can we can recruit and retain women into a trial using this treatment. we will recruit 30 women aged 18 or over, with pelvic pain and a diagnosis of endometriosis within the last three years. participants will complete informed consent, be willing to comply with the treatment and use contraception throughout the trial. we will recruit patients over six months at royal infirmary of edinburgh. women who consent will take a daily dose of dca capsules for 12 weeks.

Eligibility criteria:
inclusion criteria: * women aged 18 or over * weight between 50 and 100kg * pre-menopausal * superficial peritoneal endometriosis (asrm stage i or ii) at laparoscopy, performed within the last three years (and \>2 weeks from surgery) * pelvic pain for longer than six months * average pain score of ≥ 4 over the four weeks prior to treatment * willing to comply with the treatment * willing to use contraception throughout the trial * willing and able to complete informed consent exclusion criteria: * evidence of ovarian endometrioma or deep endometriosis (based upon current surgical staging or most recent imaging) * women who are pregnant or actively trying to get pregnant * known allergy or hypersensitivity to any excipient of dca * breastfeeding * clinical evidence of pre-existing neuropathy * diabetes * history of liver disease * history of kidney disease * taking part in a ctimp or other interventional non-ctimp studies * patient on combination antiretroviral therapy * history of malabsorption syndrome or substantial amount of small bowels or stomach removed

Keywords: endometriosis dichloroacetate
effect of the extract of the flour fermented with bacillus subtilis var natto dc-15 on postprandial glucose

Conditions: Prediabetes

Summary: the purpose of the present study is to evaluate the effect of the extract of the flour fermented with bacillus subtilis var natto dc-15 on postprandial glucose level in subjects with prediabetes.


Eligibility criteria:
inclusion criteria: * fasting plasma glucose 110-125 mg/dl exclusion criteria: * taking anti-diabetic drugs * taking drugs or functional food that may affect blood glucose level * pregnant or nursing a child * participation in any clinical trial within 90 days of the commencement of the trial * renal or hepatic dysfunction * heart disease * history of severe disease and/or major surgery
anti-inflammatory treatment for inactive takayasu arteritis

Conditions: Takayasu Arteritis; Anti-Inflammatory Agents

Summary: currently, the traditional disease activity of takayasu arteritis is mainly based on national institutes of health criteria and the inactive cases don't need anti-inflammatory treatment. however, pathologic findings showed that there was still inflammatory activity in the affected vessels, and the follow-up data also found significant lesion progression in some inactive cases. sixty inactive takayasu arteritis patients will be recruited to determine whether these individuals are active by screening new inflammatory markers in this study. new inflammatory markers included tumor necrosis factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity c-reactive protein, and 18f-fdg positron emission tomograph. according to new inflammatory markers, sixty patients will be divided into two categories: inactive patients (n=20) and active patients (n=40). and then, forty active patients diagnosed by new inflammatory markers will be randomly assigned to either anti-inflammatory therapy group or control group. the changes of inflammatory activity and lesion progression will be observed during one-year follow up in all 60 patients.


Eligibility criteria:
inclusion criteria: 1. takayasu arteritis diagnosed by the american college of rheumatology 1990 criteria; 2. inactive takayasu arteritis according to national institutes of health criteria; 3. age ≥ 14 and ≤ 40 years old at the time of informed consent; 4. patients or guardian agree to participate in the study. exclusion criteria: 1. active takayasu arteritis according to national institutes of health criteria; 2. poor compliance, intolerance to or poor response to hormone therapy; 3. allergy to contrast agent; 4. renal insufficiency (serum creatinine \>133μmol/l), cardiac insufficiency (nyha functional class iii and iv) or abnormal liver function (alanine transaminase \>1.5 times upper limit of normal)

Keywords: takayasu arteritis anti-inflammatory agents positron emission tomography computed tomography
a psychotherapy development study for internet gaming

Conditions: Internet Gaming Disorder

Summary: the fifth edition of the diagnostic and statistical manual for mental disorders (dsm-5) introduces internet gaming disorder (igd) as a substance-related and addictive disorder in section 3, conditions for further study. although research is in the nascent stages, existing studies demonstrate that igd is associated with psychosocial distress including suicidality, and adverse vocational and educational outcomes in youth. internet gaming disorder also shares substantial overlap with substance use, and it primarily affects adolescents, who rarely seek treatment on their own. parents more often express concerns about their child's game playing behaviors, and data suggest that parents can have strong influences on it. this psychotherapy development study will evaluate feasibility, acceptability, and effect sizes of a behavioral intervention designed to help parents reduce gaming problems in their children. sixty concerned parents and their children will complete parental and self-report inventories and structured diagnostic interviews regarding the child's gaming behaviors, substance use and psychosocial functioning. participants will be randomized to either a control condition consisting of referral for mental health issues and family support services or to the same plus a 6-week family-based behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors and encouraging and rewarding alternatives to game playing. gaming and other problems will be assessed pre-treatment, mid-treatment, at the end of treatment, and at a 4-month follow-up. this study is unique in evaluating initial psychometric properties of a parental version of a measure that uses the dsm-5 criteria for igd in a clinical sample, and it will also assess associations of igd with substance use, psychological symptoms, and family functioning over time. most importantly, this study will be the first randomized trial of an intervention designed to reduce gambling problems, and results are likely to guide future research and treatment efforts related to this condition.


Eligibility criteria:
inclusion criteria: * parent/guardian of a 10-19 year old residing in the same household \>8 months/year * reports significant problems with game playing exclusion criteria: * have a condition that may hinder study participation
autoimmunity contributes to the severe progression of covid-19

Conditions: Coronavirus Disease 2019

Summary: although elderliness and chronic comorbidities such as hypertension, diabetes, cardiovascular diseases and respiratory diseases, are known risk factors for severe progression of covid-19, it still remains puzzling on why younger patients without any comorbidity advance to severity and even more rapidly, the underlying mechanisms for severe progression of covid-19 still needs to be elucidated. based on current picturing of the covid-19, similar to sars, besides direct viral toxicity, immune-mediated attack derived from either the release of pro-inflammatory cytokine perpetual cascade, or secondary pathogen-induced autoimmunity response may also play important roles on disease progression and partly account for the multi-system injuries related with covid-19. virus infection has been implicated in the initiation of autoimmunity, which can attack multiple systems. with the knowledge of characteristics of sars, high level of autoimmune activity was shown to make severe injuries to lungs or other organs, leading to poor outcome including multi-system failure9. covid-19 may also get autoimmunity involved which is of obviously younger and female population predominance during the pathogenesis, no matter pre-existing or secondary to viral infection. particularly strong immune response to sars-cov-2 infection might not be protective, but perhaps, be harmful to the host, contributing to disease severe progression.


Eligibility criteria:
inclusion criteria: 1. adult inpatients from two centers, zhongnan hospital of wuhan university and thunder god mountain hospital, wuhan, china. 2. experimental confirmed covid-19 patients. 3. patients tested with autoimmunological detections including either ana+ena (antinuclear antibody + anti-extractable nuclear antigen antibody), anti-cardiolipin antibody (aca), rheumatoid factor (rf), or anti-streptolysin o antibody (aso) detection. exclusion criteria: 1. minors. 2. experimental un-confirmed covid-19 patients. 3. patients without autoimmunological detections.
effect of vitamin d on hormonal, metabolic and cardiovascular risk factors in patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: this is a double blind randomised placebo-controlled study involving women with polycystic ovary syndrome (pcos). the patients will be randomised either to vitamin d 3200 iu or placebo for three months. the main hypothesis of this study is "vitamin d improves hormonal, metabolic and cardiovascular risk markers in women with pcos".

polycystic ovary syndrome (pcos) is a very common condition in women which could present with irregular periods, excessive hair growth on body, acne and cysts in the ovaries. pcos is also associated with increased risk of problems later in life like diabetes, high cholesterol levels and heart disease. one of the risk factors for having increased incidence of such problems in pcos patients could be low vitamin d levels as many women with polycystic ovary syndrome (pcos) are vitamin d deficient. vitamin d supplementation may have a beneficial effect on insulin levels and fat around the abdomen. it has been seen in previous research studies that low level of vitamin d is related to a greater risk of diabetes and heart disease. low vitamin d levels are also associated with fat in the liver. the amount of fat in the liver is a sign of early liver disease. so, in this study the investigators want to supplement women having pcos and vitamin d deficiency with vitamin d (3,200 iu) and examine the effects on hormones related to pcos and risk factors for diabetes and heart disease in them.

Eligibility criteria:
inclusion criteria: 1. caucasian women, aged 18-45 years, with confirmed diagnosis of pcos based on all three diagnostic criteria of the rotterdam consensus \[21\]. 2. irregular periods with raised fai 3. vitamin d \< 50 nmol/l. exclusion criteria: 1. non-classical 21-hydroxylase deficiency, hyperprolactinaemia, cushing's disease and androgen-secreting tumours will be excluded by appropriate tests if clinically indicated. 2. any concurrent illness including type 2 diabetes, subjects who are on any medication (including medications that interfere with calceotrophic hormones) for the preceding 6 months. 3. women planning to conceive. 4. women who are using any oral or implantable contraceptives or any other treatments likely to affect ovarian function, insulin sensitivity or lipids for at least 3 months before entering the study. stable dose of metformin for 3 months is allowed. subjects will be advised to use barrier contraception during the study period. 5. egfr\<60. 6. hypersensitivity to vitamin d or any of the excipients in the product. 7. peanut or soya allergy. 8. nephrolithiasis. 9. diseases or conditions resulting in hypercalcaemia and/or hypercalciuria.
ultrasound guided cannulation of dialysis fistulas

Conditions: Haemodialysis

Summary: the investigators suspect that using ultrasound to guide insertion of needles for dialysis patients will make this process quicker and more accurate, thus reducing complications and reducing discomfort for patients.

haemodialysis patients need to have two needles inserted into a large surgically altered vein (fistula) or surgical vascular graft/shunt for every dialysis session. some fistulas or shunts may be more difficult to insert needles into than others. as such a system of colour coding or "traffic lighting" of patients is in place in most units. a "green light" patient is easy to "needle" with two needles and the majority of staff within the unit will be able to connect the patients to the dialysis machine. a "red light" patient is reserved for the more experienced staff within the unit who will often have to be timetabled to work specific times so that they are present to connect certain patients to the dialysis machines. "amber light" fistulas lie between these two extremes. ultrasound (us) is routinely used in many hospitals and many dialysis units will have access to a machine to assess patients for problems. indeed central venous line insertions for dialysis are now almost always performed under us guidance since two large studies in this area in 2002 provided strong evidence that us guided placement significantly reduces complications during catheter placement and a reduction in the number of attempts at insertion. in addition the national institute of clinical excellence in the uk provided evidence that insertion time is quicker although this association was statistically less convincing. ultrasound offers the advantage of dynamic imaging without the risks of radiation exposure and can be done as an office based procedure using portable equipment. studies in emergency departments and particularly in paediatric care have suggested that us guidance can improve the speed and accuracy of cannulation in peripheral veins for intravenous access. we suggest that us guided cannulation of fistulas might improve the cannulation rate of more difficult fistulas and potentially reduce the time required to commence dialysis and the number of local complications of cannulation (haematoma/aneurysm/infection). to our knowledge us is not used in cannulation guidance in any dialysis units, although most units will have access to a machine as above. we therefore propose to perform a randomised controlled trial of us guided cannulation of fistulas versus current practice (blind cannulation) to assess the effectiveness of us controlled cannulation in a busy dialysis unit.

Eligibility criteria:
inclusion criteria: 1. dialysis 3x per week 2. dialysing via 2 needles in fistula 3. no deviation from routine dialysis protocol (additional or no heparin etc) exclusion criteria: a. active or recent fistula infection/thrombosis/intervention in 6/52 of study withdrawal criteria: 1. patient request 2. patient non compliance with study protocol

Keywords: duplex ultrasound haemodialysis vascular access
outcomes after intravenous alteplase / tenecteplase with or without shuxuetong injection in routine clinical practice

Conditions: Ischemic Stroke, Acute

Summary: acute ischemic stroke is one of the main diseases leading to high risk of disability and morbidity worldwide. since intravenous thrombolysis(ivt) can effectively improve the long-term functional prognosis of acute ischemic stroke(ais), ivt within 4.5 hours of onset has been widely recommended by international guidelines. although 35-53% of ais patients achieve functional independence after receiving ivt, there are still a large number of patients who are disabled or even dead, and nearly 70% of patients have ineffective recanalization. therefore, there is an urgent need for therapeutic drugs after ivt to further improve the prognosis and reduce the burden of ais. shuxuetong injection is widely used in china in patients with ais after ivt, but the situation in real clinical practice is unclear. therefore, the study aims to evaluate the effectiveness and safety of shuxuetong injection in patients with ais treated with intravenous alteplase and tenecteplase, and obtain high-quality clinical evidence.


Eligibility criteria:
inclusion criteria: * hospitalized patients aged ≥18 years * diagnosis of acute ischemic stroke * receiving alteplase or tenecteplase treatment ≤ 4.5 hours of onset * signed informed consent by patient or legally authorized representatives exclusion criteria: * having received or planing to undergo endovascular therapy (including mechanical thrombectomy, arterial thrombolysis, angioplasty, etc.) * life expectancy is less than 90 days * other factors that the researchers think are not suitable for participating in the research * currently receiving any experimental treatment

Keywords: shuxuetong injection intravenous thrombolysis patient registry
clinical trial of use of autologous bone marrow stem cells seeded on porous tricalcium phosphate matrix and demineralized bone matrix in patients with osteonecrosis

Conditions: Osteonecrosis of Jaw

Summary: the purpose of this study is to evaluate the safety of use of autologous bone marrow stem cells seeded on porous tricalcium phosphate matrix and demineralized bone matrix in patients with osteonecrosis of the jaw by a prospective, single-center, open, nonrandomized and unblinded clinical trial.


Eligibility criteria:
inclusion criteria: * diagnosis of mandibular osteonecrosis of any etiology defined by clinical and radiological examination. * bone defect anteroposterior dimension less than or equal to 4 cm in the mandible or the maxilla 2.5, and / or bone bed sufficient to ensure the integrity of the construct during surgery. * no response to conservative treatment. * provide sufficient assurance of adherence to protocol. * provide written consent * meet all the inclusion criteria exclusion criteria: * concomitant psychiatric illness. * uncontrolled concomitant systemic disease. * active infectious disease in the focus of mandibular osteonecrosis. * neoplastic disease in complete remission less than 2 years. * pregnant patients. * patients with active feeding. * patients physically fertile, defined as all women physiologically capable of becoming pregnant, unless they are using reliable methods of contraception. * patients with cardiac disease, renal, hepatic, systemic, immune that may influence patient survival during the test. * inclusion in other clinical trials in active treatment. * inability to understand the informed consent. * you need not meet any exclusion criteria